{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:15:30Z","timestamp":1783181730693,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32300640"],"award-info":[{"award-number":["32300640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170803"],"award-info":[{"award-number":["82170803"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GDPH Supporting Fund for Talent Program","award":["KJ012020629"],"award-info":[{"award-number":["KJ012020629"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-03859-4","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T01:05:01Z","timestamp":1719882301000},"page":"1446-1455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune checkpoint inhibitors-related endocrinopathies exhibit increased severity in breast cancer patients: a real-world study"],"prefix":"10.1007","volume":"85","author":[{"given":"Rili","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheukfai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"issue":"17","key":"3859_CR1","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.35730","volume":"9","author":"S Zhao","year":"2019","unstructured":"S. Zhao, X.Y. Liu, X. Jin, D. Ma, Y. Xiao, Z.M. Shao, Y.Z. Jiang, Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer. Theranostics 9(17), 4935\u20134945 (2019)","journal-title":"Theranostics"},{"issue":"9","key":"3859_CR2","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"P. Schmid, J. Cortes, L. Pusztai, H. McArthur, S. K\u00fcmmel, J. Bergh, C. Denkert, Y.H. Park, R. Hui, N. Harbeck et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382(9), 810\u2013821 (2020)","journal-title":"N Engl J Med"},{"issue":"10265","key":"3859_CR3","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"J. Cortes, D.W. Cescon, H.S. Rugo, Z. Nowecki, S.A. Im, M.M. Yusof, C. Gallardo, O. Lipatov, C.H. Barrios, E. Holgado et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265), 1817\u20131828 (2020)","journal-title":"Lancet"},{"issue":"3","key":"3859_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"J. Cortes, H.S. Rugo, D.W. Cescon, S.A. Im, M.M. Yusof, C. Gallardo, O. Lipatov, C.H. Barrios, J. Perez-Garcia, H. Iwata et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 387(3), 217\u2013226 (2022)","journal-title":"N Engl J Med"},{"issue":"22","key":"3859_CR5","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"P. Schmid, S. Adams, H.S. Rugo, A. Schneeweiss, C.H. Barrios, H. Iwata, V. Di\u00e9ras, R. Hegg, S.A. Im, G. Shaw Wright et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 379(22), 2108\u20132121 (2018)","journal-title":"N Engl J Med"},{"issue":"1","key":"3859_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"P. Schmid, H.S. Rugo, S. Adams, A. Schneeweiss, C.H. Barrios, H. Iwata, V. Di\u00e9ras, V. Henschel, L. Molinero, S.Y. Chui et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1), 44\u201359 (2020)","journal-title":"Lancet Oncol"},{"issue":"10","key":"3859_CR7","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","volume":"2","author":"CF Friedman","year":"2016","unstructured":"C.F. Friedman, T.A. Proverbs-Singh, M.A. Postow, Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2(10), 1346\u20131353 (2016)","journal-title":"JAMA Oncol"},{"issue":"2","key":"3859_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"M.A. Postow, R. Sidlow, M.D. Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 378(2), 158\u2013168 (2018)","journal-title":"N Engl J Med"},{"issue":"1","key":"3859_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"L.S. Chang, R. Barroso-Sousa, S.M. Tolaney, F.S. Hodi, U.B. Kaiser, L. Min, Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev 40(1), 17\u201365 (2019)","journal-title":"Endocr Rev"},{"key":"3859_CR10","doi-asserted-by":"crossref","unstructured":"F. Albarel, F. Castinetti, T. Brue, MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. Eur J Endocrinol 181(3), R107-r118 (2019)","DOI":"10.1530\/EJE-19-0169"},{"issue":"21","key":"3859_CR11","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"J.S. Weber, K.C. K\u00e4hler, A. Hauschild, Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21), 2691\u20132697 (2012)","journal-title":"J Clin Oncol"},{"issue":"3","key":"3859_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1056\/NEJMra050776","volume":"354","author":"JD Yager","year":"2006","unstructured":"J.D. Yager, N.E. Davidson, Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3), 270\u2013282 (2006)","journal-title":"N Engl J Med"},{"issue":"2","key":"3859_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1210\/endrev\/bnz001","volume":"41","author":"B Trabert","year":"2020","unstructured":"B. Trabert, M.E. Sherman, N. Kannan, F.Z. Stanczyk, Progesterone and Breast Cancer. Endocr Rev 41(2), 320\u2013344 (2020)","journal-title":"Endocr Rev"},{"issue":"10286","key":"3859_CR14","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"S. Loibl, P. Poortmans, M. Morrow, C. Denkert, G. Curigliano, Breast cancer. Lancet 397(10286), 1750\u20131769 (2021)","journal-title":"Lancet"},{"issue":"7","key":"3859_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","volume":"32","author":"CN Owen","year":"2021","unstructured":"C.N. Owen, X. Bai, T. Quah, S.N. Lo, C. Allayous, S. Callaghan, C. Mart\u00ednez-Vila, R. Wallace, P. Bhave, I.L.M. Reijers et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 32(7), 917\u2013925 (2021)","journal-title":"Ann Oncol"},{"issue":"1","key":"3859_CR16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","volume":"7","author":"MA Couey","year":"2019","unstructured":"M.A. Couey, R.B. Bell, A.A. Patel, M.C. Romba, M.R. Crittenden, B.D. Curti, W.J. Urba, R.S. Leidner, Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer 7(1), 165 (2019)","journal-title":"J Immunother Cancer"},{"key":"3859_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.04.025","volume":"134","author":"O Nigro","year":"2020","unstructured":"O. Nigro, G. Pinotti, F. De Galitiis, F.R. Di Pietro, R. Giusti, M. Filetti, M. Bersanelli, A. Lazzarin, P. Bordi, A. Catino et al. Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: A multicentre study. Eur J Cancer 134, 19\u201328 (2020)","journal-title":"Eur J Cancer"},{"issue":"17","key":"3859_CR18","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino, I. Chau, M.S. Ernstoff, J.M. Gardner, P. Ginex et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36(17), 1714\u20131768 (2018)","journal-title":"J Clin Oncol"},{"issue":"7","key":"3859_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"J.J. Wright, A.C. Powers, D.B. Johnson, Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17(7), 389\u2013399 (2021)","journal-title":"Nat Rev Endocrinol"},{"key":"3859_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0073-4","volume":"5","author":"MH Tan","year":"2019","unstructured":"M.H. Tan, R. Iyengar, K. Mizokami-Stout, S. Yentz, M.P. MacEachern, L.Y. Shen, B. Redman, R. Gianchandani, Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol 5, 1 (2019)","journal-title":"Clin Diabetes Endocrinol"},{"key":"3859_CR21","doi-asserted-by":"crossref","unstructured":"J.H.L. Chieng, Z.W. Htet, J. J. Zhao, E.S. Tai, S. H. Tay, Y. Huang, A. Wong, S.P. Yang, Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment. Cancers (Basel) 14(11), 2687 (2022)","DOI":"10.3390\/cancers14112687"},{"issue":"2","key":"3859_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro, F.S. Hodi, L. Min, I.E. Krop, S.M. Tolaney, Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 4(2), 173\u2013182 (2018)","journal-title":"JAMA Oncol"},{"issue":"12","key":"3859_CR23","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","volume":"6","author":"B Shankar","year":"2020","unstructured":"B. Shankar, J. Zhang, A.R. Naqash, P.M. Forde, J.L. Feliciano, K.A. Marrone, D.S. Ettinger, C.L. Hann, J.R. Brahmer, B. Ricciuti et al. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer. JAMA Oncol 6(12), 1952\u20131956 (2020)","journal-title":"JAMA Oncol"},{"key":"3859_CR24","doi-asserted-by":"crossref","unstructured":"A. D\u2019Aiello, J. Lin, R. Gucalp, V. Tabatabaie, H. Cheng, N.A. Bloomgarden, Y. Tomer, B. Halmos, Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. Cancers (Basel), 13(6), 1464 (2021)","DOI":"10.3390\/cancers13061464"},{"issue":"11","key":"3859_CR25","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1097\/RLU.0000000000000887","volume":"40","author":"S Bacanovic","year":"2015","unstructured":"S. Bacanovic, I.A. Burger, P. Stolzmann, J. Hafner, M.W. Huellner, Ipilimumab-Induced Adrenalitis: A Possible Pitfall in 18F-FDG-PET\/CT. Clin Nucl Med 40(11), e518\u2013e519 (2015)","journal-title":"Clin Nucl Med"},{"issue":"3","key":"3859_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"J. de Filette, C.E. Andreescu, F. Cools, B. Bravenboer, B. Velkeniers, A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. Horm Metab Res 51(3), 145\u2013156 (2019)","journal-title":"Horm Metab Res"},{"issue":"4","key":"3859_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1517\/14712598.2016.1128891","volume":"16","author":"AM Grimaldi","year":"2016","unstructured":"A.M. Grimaldi, F.M. Marincola, P.A. Ascierto, Single versus combination immunotherapy drug treatment in melanoma. Expert Opin Biol Ther 16(4), 433\u2013441 (2016)","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 4","key":"3859_CR28","doi-asserted-by":"publisher","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","volume":"29","author":"J Haanen","year":"2018","unstructured":"J. Haanen, F. Carbonnel, C. Robert, K.M. Kerr, S. Peters, J. Larkin, K. Jordan,Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4), iv264\u2013iv266 (2018)","journal-title":"Ann Oncol"},{"key":"3859_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","volume":"47","author":"P Iglesias","year":"2018","unstructured":"P. Iglesias, Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. Eur J Intern Med 47, 6\u201313 (2018)","journal-title":"Eur J Intern Med"},{"issue":"3","key":"3859_CR30","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","volume":"1","author":"L Min","year":"2013","unstructured":"L. Min, N. Ibrahim, Ipilimumab-induced autoimmune adrenalitis. Lancet Diabetes Endocrinol 1(3), e15 (2013)","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"3859_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/1756287217748867","volume":"10","author":"S Osanto","year":"2018","unstructured":"S. Osanto, T. van der Hulle, Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Ther Adv Urol 10(3), 109\u2013123 (2018)","journal-title":"Ther Adv Urol"},{"issue":"17","key":"3859_CR32","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","volume":"25","author":"SA Weiss","year":"2019","unstructured":"S.A. Weiss, J.D. Wolchok, M. Sznol, Immunotherapy of Melanoma: Facts and Hopes. Clin Cancer Res 25(17), 5191\u20135201 (2019)","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3859_CR33","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.2337\/dc18-2556","volume":"42","author":"IF Muhammad","year":"2019","unstructured":"I.F. Muhammad, Y. Born\u00e9, X. Bao, O. Melander, M. Orho-Melander, P.M. Nilsson, J. Nilsson, G. Engstr\u00f6m, Circulating HER2\/ErbB2 Levels Are Associated With Increased Incidence of Diabetes: A Population-Based Cohort Study. Diabetes Care 42(8), 1582\u20131588 (2019)","journal-title":"Diabetes Care"},{"issue":"9","key":"3859_CR34","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1007\/s13277-015-3380-8","volume":"36","author":"L Juanjuan","year":"2015","unstructured":"L. Juanjuan, W. Wen, L. Zhongfen, C. Chuang, C. Jing, G. Yiping, W. Changhua, Y. Dehua, S. Shengrong, Clinical pathological characteristics of breast cancer patients with secondary diabetes after systemic therapy: a retrospective multicenter study. Tumour Biol 36(9), 6939\u20136947 (2015)","journal-title":"Tumour Biol"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03859-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03859-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T06:22:04Z","timestamp":1723270924000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03859-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["3859"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03859-4","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,29]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Review Committee of Guangdong Provincial People\u2019s Hospital (Date:2021-10-12\/Ethics number: KY-Q-2021-191-01).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}